AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan

onsdag, 2 september 2015

AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) an exclusive license to develop and commercialise FluMist® Quadrivalent in Japan.

FluMist Quadrivalent is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains. Phase III safety and efficacy studies were conducted for FluMist Quadrivalent in Japanese children over the 2014-2015 influenza season and a regulatory submission is being prepared in Japan.

Under the terms of the agreement, Daiichi Sankyo will pay AstraZeneca an upfront fee with subsequent development milestones and sales-related payments post launch. Daiichi Sankyo will take on the full responsibility for the future development and commercialisation of FluMist Quadrivalent in Japan and will hold the marketing authorisation; AstraZeneca will supply FluMist Quadrivalent to Daiichi Sankyo.

Marc Dunoyer, Chief Financial Officer and senior executive team member responsible for Japan, said: “We’re pleased to enter into this agreement with Daiichi Sankyo, whose specific expertise in developing and commercialising innovative vaccines will help ensure we bring FluMist Quadrivalent to as many children as possible in Japan.”

Takeshi Ogita, Member of the Board & Head of Vaccine Business Unit, Daiichi Sankyo, said: “We are proud to be able to deliver, once approved, FluMist Quadrivalent to Japanese children and adolescents and to make a contribution to public health by protecting people from influenza.”

The transaction reflects AstraZeneca’s business model, which includes collaborating with companies that have the expertise, focus and resources to maximise the potential of the company’s innovative medicines for the benefit of patients and shareholders. The agreement builds on the successful collaborations between AstraZeneca and Daiichi Sankyo, such as the co-commercialisation of NEXIUM® in Japan and MOVANTIK™ in the US.

The agreement does not impact AstraZeneca’s financial guidance for 2015.

NOTES TO EDITORS

About FluMist

FluMist Quadrivalent (US brand name) / Fluenz™ Tetra (EU brand name) is the most widely available quadrivalent live attenuated influenza vaccine (LAIV), which is administered as a nasal spray and contains four protective strains for the prevention of influenza. Over 150,000 people have received FluMist/Fluenz in pre-approval and post-marketing clinical studies.

FluMist was originally approved in the US in 2003 and later in other markets. Since the original approval, more than 100 million doses have been distributed around the world.

Preferential recommendations for LAIV have been adopted in the UK, Canada, Israel, Finland, Sweden (high-risk individuals) and Germany (high-risk individuals). A general recommendation for quadrivalent LAIV in people aged two to 49 has been adopted in the US.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidaemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit: www.daiichisankyo.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

CONTACTS

Media Enquiries

Esra Erkal-Paler UK/Global +44 20 7604 8030
Vanessa Rhodes UK/Global +44 20 7604 8037
Ayesha Bharmal UK/Global +44 20 7604 8034
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677

Investor Enquiries
UK

Thomas Kudsk Larsen +44 20 7604 8199 +44 7818 524185
Eugenia Litz RIA +44 20 7604 8233 +44 7884 735627
Nick Stone CVMD +44 20 7604 8236 +44 7717 618834
Karl Hård Oncology +44 20 7604 8123 +44 7789 654364
Craig Marks ING +44 20 7604 8591 +44 7881 615764
Christer Gruvris +44 20 7604 8126 +44 7827 836825

US

Lindsey Trickett ING +1 301 398 5118 +1 301 398 5118
Dial / Toll-Free +1 301 398 3251 +1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,  ING - Infection, Neuroscience and Gastrointestinal

tags

  • Corporate
  • Infektion